echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The domestically produced new crown drug is expected to be approved for conditional listing before the end of December

    The domestically produced new crown drug is expected to be approved for conditional listing before the end of December

    • Last Update: 2022-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 22, according to the People’s Daily, the new crown drug BRII-196 and BRII-198 jointly developed by Tsinghua University, Shenzhen Third People’s Hospital and Tengsheng Bo Pharmaceutical has been unblinded in clinical phase III, and the drug delivery group is in treatment After 28 days, zero deaths were achieved, and 8 cases in the control group died.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.